- Neuronetics Inc. stim When Greenbrook TMS Inc GBNH announced an expansion of its commercial partnership through the end of 2028.
- Under the partnership agreement, Neuronetics will be the exclusive supplier of transcranial magnetic stimulation (TMS) devices to Greenbrook. Over time, Neuronetics’ NeuroStar device will replace his competing TMS device at the Greenbrook location.
- The contract also has a minimum purchase amount and all treatment session purchases are converted to a “per click” consumable model.
- Keith J. Sullivan, CEO of Neuronetics, said:
- Greenbrook CEO Bill Leonard said: hindrance. “
- Price action: At the final check on Thursday, STIM shares fell 0.68% to $5.80.
© 2023 Benzinga.com. Benzinga does not provide investment advice. all rights reserved.